Biophytis S.A. - Asset Resilience Ratio
Biophytis S.A. (ALBPS) has an Asset Resilience Ratio of 16.07% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALBPS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Biophytis S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Biophytis S.A.'s balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Biophytis S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ALBPS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €850.00K | 12.83% |
| Short-term Investments | €214.00K | 3.23% |
| Total Liquid Assets | €1.06 Million | 16.07% |
Asset Resilience Insights
- Good Liquidity Position: Biophytis S.A. maintains a healthy 16.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biophytis S.A. Industry Peers by Asset Resilience Ratio
Compare Biophytis S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Biophytis S.A. (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Biophytis S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.75% | €190.00K ≈ $222.13K |
€6.90 Million ≈ $8.07 Million |
-22.98pp |
| 2023-12-31 | 25.74% | €3.08 Million ≈ $3.60 Million |
€11.96 Million ≈ $13.98 Million |
+0.34pp |
| 2022-12-31 | 25.39% | €5.58 Million ≈ $6.53 Million |
€21.99 Million ≈ $25.71 Million |
+2.70pp |
| 2021-12-31 | 22.69% | €8.23 Million ≈ $9.62 Million |
€36.26 Million ≈ $42.39 Million |
-32.43pp |
| 2020-12-31 | 55.13% | €15.00 Million ≈ $17.54 Million |
€27.21 Million ≈ $31.81 Million |
+52.44pp |
| 2019-12-31 | 2.69% | €475.00K ≈ $555.32K |
€17.67 Million ≈ $20.66 Million |
-43.05pp |
| 2018-12-31 | 45.74% | €10.00 Million ≈ $11.69 Million |
€21.86 Million ≈ $25.56 Million |
+9.21pp |
| 2016-12-31 | 36.53% | €3.07 Million ≈ $3.58 Million |
€8.39 Million ≈ $9.81 Million |
+36.53pp |
| 2015-12-31 | 0.00% | €367.00 ≈ $429.06 |
€13.52 Million ≈ $15.80 Million |
-24.83pp |
| 2012-12-31 | 24.84% | €300.49K ≈ $351.31K |
€1.21 Million ≈ $1.41 Million |
-- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more